Julia Haehl

Julia Haehl

Auto-generated profile, based on publicly available information

Julia Haehl

Department of Pediatric Surgery, Dr. von Hauner Children’s Hospital, University Hospital, LMU Munich, Munich, Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
Vanessa F. SchmidtVanessa F. Schmidt
Vanessa F. Schmidt
Friedrich G. KappFriedrich G. Kapp
Friedrich G. Kapp
CGConstantin Goldann
Constantin Goldann
LHLinda Huthmann
Linda Huthmann
BCBeatrix Cucuruz
Beatrix Cucuruz
FIfor the APOLLON Investigators
for the APOLLON Investigators
Background: We aimed to correlate alterations in the rat sarcoma virus (RAS)/mitogen‐activated protein kinase pathway in vascular anomalies to the clinical phenotype for improved patient and treatment stratification. Methods and Results: This retrospective multicenter cohort study included 29 patients with extracranial vascular anomalies containing mosaic pathogenic variants (PVs) in genes of the RAS/mitogen‐activated protein kinase pathway. Tissue samples were collected during invasive treatment or clinically indicated biopsies. PVs were detected by the targeted sequencing of panels of genes known to be associated with vascular anomalies, performed using DNA from affected tissue. Subgroup analyses were performed according to the affected genes with regard to phenotypic characteristics in a descriptive manner. Twenty‐five vascular malformations, 3 vascular tumors, and 1 patient with both a vascular malformation and vascular tumor presented the following distribution of PVs in genes: Kirsten rat sarcoma viral oncogene (n=10), neuroblastoma ras viral oncogene homolog (n=1), Harvey rat sarcoma viral oncogene homolog (n=5), V‐Raf murine sarcoma viral oncogene homolog B (n=8), and mitogen‐activated protein kinase kinase 1 (n=5). Patients with RAS PVs had advanced disease stages according to the Schobinger classification (stage 3–4: RAS , 9/13 versus non‐ RAS , 3/11) and more frequent progression after treatment ( RAS , 10/13 versus non‐ RAS , 2/11). Lesions with Kirsten rat sarcoma viral oncogene PVs infiltrated more tissue layers compared with the other PVs including other RAS PVs (multiple tissue layers: Kirsten rat sarcoma viral oncogene, 8/10 versus other PVs, 6/19). Conclusions: This comparison of patients with various PVs in genes of the RAS/MAPK pathway provides potential associations with certain morphological and clinical phenotypes. RAS variants were associated with more aggressive phenotypes, generating preliminary data and hypothesis for future larger studies.

1 September 2025 in Journal of Pediatric Surgery
Verified
Journal Article
Open access
JHJulia Haehl
Julia Haehl
BHBeate Haeberle
Beate Haeberle
Oliver J. MuenstererOliver J. Muensterer
Oliver J. Muensterer
AHAlexandra Hartel
Alexandra Hartel
AFAlexandra Fröba-Pohl
Alexandra Fröba-Pohl
Moritz WildgruberMoritz Wildgruber
Moritz Wildgruber
Rationale and Objectives Bleomycin electrosclerotherapy (BEST) is a promising treatment for slow-flow vascular malformations (SFVMs). Due to limited paediatric data, this study aimed to assess the safety, effectiveness, and patient-reported outcomes of BEST in children with SFVMs. Material and Methods This monocenter cohort study included patients <18 years with symptomatic SFVMs treated by BEST. Patient records were analysed for procedural details and complications. Symptom severity was objectively classified before and after BEST. A treatment-specific, patient-reported questionnaire assessed mobility, aesthetic concerns, swelling, social participation, pain using a visual analogue scale (VAS), and post-procedural skin discoloration. Outcomes were compared between simple and infiltrative lesions. Results Overall, 68 BEST sessions were performed in 45 children. Total complication rate was 10/68 (14.7%), most commonly pes equinus deformities (5/68, 7.4%) after treating SFVMs in calf muscles. Physician-rated overall symptom severity improved significantly (p<0.001). Treatment-specific, patient-reported questionnaire revealed improved mobility in 14/41 (34.1%) and symptom-free patients in 10/41 (24.4%). Outcome in both aesthetic measure and social participation was mostly rated as improved or perfect (33/41, 80.5%; 35/41, 85.4%). Median VAS pain scale improved significantly (2.0 vs. 0.0, p<0.001). Postprocedural swelling occurred in all children, in 26/41 cases (64.4%) persisting for 2-4 weeks. Postprocedural skin discoloration (41/41, 100%) was mostly (25/41, 61.0%) reported to fade over time. No differences between simple and infiltrative lesions were revealed in all outcome parameters. Conclusion BEST is effective for paediatric SFVMs by objective and subjective measures while maintaining low complication rates. Notably, BEST achieves therapeutic success even in infiltrative SFVMs expanding the range of available treatment options.

10 February 2025 in Journal of Pediatric Surgery
Verified
Journal Article
Open access
KHKayoung Heo
Kayoung Heo
EGEric Greaney
Eric Greaney
JHJulia Haehl
Julia Haehl
CSChelsea Stunden
Chelsea Stunden
ALAndreas Lindner
Andreas Lindner
SJShahrzad Joharifard
Shahrzad Joharifard
Inguinal hernia is a common childhood pathology, making inguinal hernia repair (IHR) a key pediatric surgical procedure. Surgical success relies heavily on knowledge of groin anatomy, and both open and laparoscopic approaches require considerable repetition to master. As surgical simulators have been shown to improve performance for other surgical procedures, we developed a combined open and laparoscopic pediatric IHR simulator-named POLISHeR-to train residents, fellows, and practicing surgeons in both types of repair. A CT scan of a 7-year-old was scaled down to create a virtual 3D model of a 2-year-old using our validated protocol for anatomical modelling. Physical replicas of the pelvis, abdominal wall, aorta, and inferior vena cava were 3D-printed to create a life-size unisex base for open and laparoscopic IHR, while a small mobile unisex base was 3D-printed for open IHR. We recruited six experienced surgeons and trainees to pilot the face validity of POLISHeR. After multiple iterations, we successfully developed a modular 3D-printed simulator for open and laparoscopic IHR. Printing the life-size base cost $331.69 USD, whereas the small base cost $17.54. An open modular cartridge cost $9.92 for females and $14.21 for males, whereas replacement parts cost under $1.30. A laparoscopic modular cartridge cost $6.16 for females and $10.91 for males, whereas replacement parts cost $0.28. Pilot study participants provided encouraging feedback with respect to POLISHER's face validity. Our low-cost simulator holds promise for enhancing training for pediatric IHR. Our next step is to conduct validation trials for trainees and practicing surgeons in both well-resourced and resource-limited settings. Not applicable.

16 July 2025 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
HLHannah Lea Luz
Hannah Lea Luz
JHJulia Haehl
Julia Haehl
CLClara Franziska Luz
Clara Franziska Luz
SZSabine Zundel
Sabine Zundel

29 January 2026 in Journal of Pediatric Surgery
Verified
Journal Article
Open access
PMPeter R.A. Malik
Peter R.A. Malik
JHJulia Haehl
Julia Haehl
RLRachel Livergant
Rachel Livergant
LSLukas Shum-Tim
Lukas Shum-Tim
KHKayoung Heo
Kayoung Heo
SJShahrzad Joharifard
Shahrzad Joharifard
Pediatric inguinal hernia repair (PIHR) is a common procedure performed using either open or laparoscopic techniques. Both approaches require detailed anatomical knowledge and specialized training. To address these training needs, we developed a low-cost, 3D-printed Pediatric Open and Laparoscopic Integrated Simulator for Inguinal Hernia Repair (POLISHeR). This study aimed to validate POLISHeR as a simulation tool for essential PIHR skills. Experienced pediatric surgeons and surgical trainees performed simulated PIHR using POLISHeR. Participants evaluated the simulator's face and content validity using a 5-point Likert scale. Two experienced pediatric surgeons assessed video-recorded simulations using procedure (PCL) and error (ECL) checklists. An Entrustable Professional Activity (EPA) scale measured participants' competence. Construct validity was assessed by comparing expert and trainee performance using the Mann-Whitney U test. Twenty-six participants completed simulations (open: n=11; laparoscopic: n=15), including 14 expert pediatric surgeons (open: n=5; laparoscopic: n=9). In laparoscopic PIHR, trainees made significantly more errors (p < 0.001), completed fewer key steps (p < 0.001), and received lower EPA scores (p < 0.001) than experts. In open PIHR, trainees made more errors (p = 0.03), had lower EPA scores (p = 0.05), and received lower PCL scores (p = 0.410), though not statistically significant. Experts reported strong anatomical realism and accurate step representation. POLISHeR demonstrates strong face, content, and construct validity. It effectively differentiates between expert and trainee performance and represents an affordable, practical tool for teaching and evaluating PIHR skills.

2 October 2026 in medRxiv
Verified
Preprint
Open access
PDF file
GCGabriella Cericola
Gabriella Cericola
BHBeate Häberle
Beate Häberle
JHJulia Haehl
Julia Haehl
SBSebastian Berg
Sebastian Berg
SLSimon Leschka
Simon Leschka
Friedrich G. KappFriedrich G. Kapp
Friedrich G. Kapp
Background: Localized or segmental overgrowth is a rare condition that may co-occur with vascular malformations. These diseases generally are caused by somatic mutations in the PI3K/AKT/mTOR pathway. Most lesions are progressive and may cause symptoms including pain, functional impairment, and disfigurement. Treatment options are limited, especially for the overgrowth component. Objective: To evaluate the efficacy and safety of the mTOR inhibitor sirolimus in patients with overgrowth with or without a vascular malformation over a 6-months treatment period. Methods: We conducted a single-arm, open-label, phase II study including 18 patients (12 pediatric, six adult) with overgrowth, all of whom initiated oral sirolimus. 16/18 (88.9%) participants received oral sirolimus for 6 months, with dosing adjusted to achieve target blood trough levels of 3–8 ng/mL. Primary outcome was radiological response at six months assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Secondary outcome parameters were evaluated at three, six and nine months and included size and visual appearance of the overgrowth, quality of life (QoL), pain intensity, performance status, and safety. Results: No patient achieved complete or partial radiological response. 17 of 18 patients (94.4%) maintained stable disease at month six; one was not evaluable. QoL measured with WHOQOL-BREF improved modestly in patients aged >= 18 years (n=5, mean difference to baseline +9.3 (95%-CI: -0.9 to 19.5) in physical and +9.2 (95%-CI: 0.7 to 17.7) in psychological domains at month 6). In pediatric participants, no relevant improvement in KINDL total scores was observed over the study period. No significant changes occurred in pain scores. Performance status measured by the Lansky/Karnofsky scales showed minor improvement (mean +3.5 points (95%-CI: 1.0 to 6.1)). All patients experienced at least one adverse event, but no serious adverse events or CTCAE v5.0 grade ≥3 toxicities occurred. Sirolimus was well tolerated. Six patients decided to resume sirolimus after study completion. Conclusions: Sirolimus induced minor lesion shrinkage in a subset of patients, although this did not meet the predefined radiological RECIST endpoint. However, sirolimus can lead to functional improvement in some adults, which may indicate that the primary radiological outcome did not capture patient-perceived benefit.